1

Gross Sales & Income from Operations

5695.4

5993.8

24003.3

20554.1

Less: Excise Duty

345.6

297.4

1584.1

1323.9

Net Sales & Income from Operations

5349.8

5696.4

22419.2

19230.2

2

Other Income

154.5

109.5

759.4

355.7

3

Total Expenditure

a) (Increase)/decrease in
     Stock-in-trade

(517.2)

51.1

(703.3)

206.1

b) Consumption of Materials

2735.8

2938.3

11678.8

9663.0

c) Staff Cost

320.9

258.2

1169.3

952.5

d) Other Expenditure

1441.4

1156.9

5314.3

4216.8

4

Interest

10.1

34.0

75.7

103.9

5

Depreciation

147.5

100.0

530.0

402.8

6

Profit (+)/Loss (-) before Tax
(1+2-3-4-5)

1365.8

1267.4

5113.8

4040.8

7

242.5
67.5

216.7
33.3

820.0
230.0

780.0
97.5

8

Net Profit (+) / Loss (-) after Tax and before extra-ordinary item
(6-7)

1055.8

1017.4

4063.8

3163.3

9

Extra-ordinary Expenditure

-

-

-

96.4

10

Tax - prior years'

-

-

-

111.0

11

Profit available for Appropriation
(8-9-10)

1055.8

1017.4

4063.8

2955.9

12

Paid-up Equity Share Capital

599.7

599.7

599.7

599.7

13

Reserves excluding Revaluation Reserves

 

11938.9

14

Earning per Share
*Not Annualised

*3.52

*3.39

13.55

9.86

15

Aggregate of Non-Promoter
Shareholding
- Number of Shares
- Percentage of Shareholding
- Face Value per Share (Rs.)

177070533
59.05
2/-

35406037
59.04
10/-

177070533
59.05
2/-

1. The Company is exclusively in the pharmaceutical business segment.
2. The figures of the previous year have been regrouped to render them comparable with the figures of the current year.
3. Four investor grievances were pending at the beginning of the quarter. During the quarter under review, 67 investor grievances were received. As of 31st March, 2005, all investor grievances have been suitably replied to.
4. The Company has set-up a state-of-the-art facility for manufacture of formulations at Baddi, Himachal Pradesh and commercial production has commenced during April 2005.
5. The Company had challenged the inclusion of the drugs - Salbutamol, Theophylline, Ciprofloxacin and Norfloxacin within the ambit of price control. The petition filed by the Company had been decided in favour of the Company by the Bombay High Court, which held that the said drugs were outside the ambit of price control. However, on the appeal filed by the government, the Supreme Court has remanded the matter to the Bombay High Court for further and more detailed examination in light of the principles laid down by the Supreme Court. The Supreme Court had also permitted the government to recover 50% of the amount that they had claimed was overcharged. The government had sent notices to the Company demanding an aggregate of Rs. 1803.7 million in respect of the said drugs, which according to them was 50% of the amount allegedly overcharged by the Company till July 2003. The Company had replied that the same were not payable in view of the interim orders obtained by the Company in different proceedings in the Karnataka High Court and the Allahabad High Court. Subsequently, the Allahabad High Court had ruled that the prices fixed by the government in respect of the said drugs were illegal and void. On an appeal filed by the government against this ruling the Supreme Court has stayed the judgment of the Hon'ble Allahabad High Court. Further, the Supreme Court has directed that no coercive action shall be taken against the Company till the appeal is finally decided. The Company has been advised that the demand notices of the government are not valid in view of the orders of the courts.
6. The above results were taken on record at the meeting of the Board of Directors held on 26th April, 2005.
   

-15.4%

 

70.0%

-49.2%

14.2%

-0.1%

-54.4%

-5.0%

6.0%

7.8%

3.8%